-
-
-
-
-
-
-
Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP
-
-
-
-
-
-
-
Telesta Therapeutics and Ipsen announce exclusive license agreement for MCNA(1) for the treatment of non-muscle invasive bladder cancer in major ex-United States territories
-
-
15,422 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

